Tags : WW Rights

VistaGen Therapeutics Acquires WW Rights for Pherin’s PH94B nasal spray

Shots: Pherin will receive $2.25M of unregistered common stock (1,630,435 unregistered shares) from Vista VistaGen has rights to commercialize and develop PH94B nasal spray (expected to enter in P-III in H1’19) as a PRN treatment for SAD, in addition to an option to acquire Pherin’s CNS neuropsychiatry-focused product currently under P-II The main focus of […]Read More

Laekna Acquires Exclusive WW Rights of Two Oncology Clinical Stage

Shots: Agreement involves the two oral pan-Akt kinase inhibitors afuresertib (ASB183) and uprosertib (UPB795) with >10 clinical Ph1/2 tested for cancer Accordingly, Novartis will acquire equity stake in Laenka adding upfront fees and milestones including royalties A second agreement b/w them in addition CFG920(CYP17 inhibitor) licensing, an oral androgen inhibitor, for prostate cancer Click here […]Read More